Lorelei A Mucci1, Jacob B Hjelmborg2, Jennifer R Harris3, Kamila Czene4, David J Havelick5, Thomas Scheike6, Rebecca E Graff7, Klaus Holst6, Sören Möller2, Robert H Unger5, Christina McIntosh8, Elizabeth Nuttall5, Ingunn Brandt3, Kathryn L Penney9, Mikael Hartman10, Peter Kraft11, Giovanni Parmigiani12, Kaare Christensen13, Markku Koskenvuo14, Niels V Holm15, Kauko Heikkilä14, Eero Pukkala16, Axel Skytthe2, Hans-Olov Adami17, Jaakko Kaprio18. 1. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts2Division of Public Health Sciences, University of Iceland, Reykjavik3Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School. 2. Department of Biostatistics and Epidemiology, University of Southern Denmark, Odense5Danish Twin Registry, University of Southern Denmark, Odense. 3. Division of Epidemiology, Norwegian Institute of Public Health, Oslo, Norway. 4. Department of Biostatistics and Epidemiology, University of Southern Denmark, Odense5Danish Twin Registry, University of Southern Denmark, Odense7Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 5. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 6. Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark. 7. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts9Department of Epidemiology and Biostatistics, University of California, San Francisco. 8. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 9. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 10. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden11Department of Surgery, National University Hospital and NUHS, Singapore. 11. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts10Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 12. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts12Department of Computational Biology and Biostatistics, Dana Farber Cancer Institute, Boston, Massachusetts. 13. Department of Biostatistics and Epidemiology, University of Southern Denmark, Odense. 14. University of Helsinki, Hjelt Institute, Department of Public Health, Helsinki, Finland. 15. Danish Twin Registry, University of Southern Denmark, Odense14Department of Oncology, Odense University Hospital, Odense, Denmark. 16. Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland16School of Health Sciences, University of Tampere, Tampere, Finland. 17. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts7Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. 18. University of Helsinki, Hjelt Institute, Department of Public Health, Helsinki, Finland17National Institute for Health and Welfare, Department of Health, Helsinki, Finland18University of Helsinki, Institute for Molecular Medicine, Helsinki, Finland.
Abstract
IMPORTANCE: Estimates of familial cancer risk from population-based studies are essential components of cancer risk prediction. OBJECTIVE: To estimate familial risk and heritability of cancer types in a large twin cohort. DESIGN, SETTING, AND PARTICIPANTS: Prospective study of 80,309 monozygotic and 123,382 same-sex dizygotic twin individuals (N = 203,691) within the population-based registers of Denmark, Finland, Norway, and Sweden. Twins were followed up a median of 32 years between 1943 and 2010. There were 50,990 individuals who died of any cause, and 3804 who emigrated and were lost to follow-up. EXPOSURES: Shared environmental and heritable risk factors among pairs of twins. MAIN OUTCOMES AND MEASURES: The main outcome was incident cancer. Time-to-event analyses were used to estimate familial risk (risk of cancer in an individual given a twin's development of cancer) and heritability (proportion of variance in cancer risk due to interindividual genetic differences) with follow-up via cancer registries. Statistical models adjusted for age and follow-up time, and accounted for censoring and competing risk of death. RESULTS: A total of 27,156 incident cancers were diagnosed in 23,980 individuals, translating to a cumulative incidence of 32%. Cancer was diagnosed in both twins among 1383 monozygotic (2766 individuals) and 1933 dizygotic (2866 individuals) pairs. Of these, 38% of monozygotic and 26% of dizygotic pairs were diagnosed with the same cancer type. There was an excess cancer risk in twins whose co-twin was diagnosed with cancer, with estimated cumulative risks that were an absolute 5% (95% CI, 4%-6%) higher in dizygotic (37%; 95% CI, 36%-38%) and an absolute 14% (95% CI, 12%-16%) higher in monozygotic twins (46%; 95% CI, 44%-48%) whose twin also developed cancer compared with the cumulative risk in the overall cohort (32%). For most cancer types, there were significant familial risks and the cumulative risks were higher in monozygotic than dizygotic twins. Heritability of cancer overall was 33% (95% CI, 30%-37%). Significant heritability was observed for the cancer types of skin melanoma (58%; 95% CI, 43%-73%), prostate (57%; 95% CI, 51%-63%), nonmelanoma skin (43%; 95% CI, 26%-59%), ovary (39%; 95% CI, 23%-55%), kidney (38%; 95% CI, 21%-55%), breast (31%; 95% CI, 11%-51%), and corpus uteri (27%; 95% CI, 11%-43%). CONCLUSIONS AND RELEVANCE: In this long-term follow-up study among Nordic twins, there was significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus. This information about hereditary risks of cancers may be helpful in patient education and cancer risk counseling.
IMPORTANCE: Estimates of familial cancer risk from population-based studies are essential components of cancer risk prediction. OBJECTIVE: To estimate familial risk and heritability of cancer types in a large twin cohort. DESIGN, SETTING, AND PARTICIPANTS: Prospective study of 80,309 monozygotic and 123,382 same-sex dizygotic twin individuals (N = 203,691) within the population-based registers of Denmark, Finland, Norway, and Sweden. Twins were followed up a median of 32 years between 1943 and 2010. There were 50,990 individuals who died of any cause, and 3804 who emigrated and were lost to follow-up. EXPOSURES: Shared environmental and heritable risk factors among pairs of twins. MAIN OUTCOMES AND MEASURES: The main outcome was incident cancer. Time-to-event analyses were used to estimate familial risk (risk of cancer in an individual given a twin's development of cancer) and heritability (proportion of variance in cancer risk due to interindividual genetic differences) with follow-up via cancer registries. Statistical models adjusted for age and follow-up time, and accounted for censoring and competing risk of death. RESULTS: A total of 27,156 incident cancers were diagnosed in 23,980 individuals, translating to a cumulative incidence of 32%. Cancer was diagnosed in both twins among 1383 monozygotic (2766 individuals) and 1933 dizygotic (2866 individuals) pairs. Of these, 38% of monozygotic and 26% of dizygotic pairs were diagnosed with the same cancer type. There was an excess cancer risk in twins whose co-twin was diagnosed with cancer, with estimated cumulative risks that were an absolute 5% (95% CI, 4%-6%) higher in dizygotic (37%; 95% CI, 36%-38%) and an absolute 14% (95% CI, 12%-16%) higher in monozygotic twins (46%; 95% CI, 44%-48%) whose twin also developed cancer compared with the cumulative risk in the overall cohort (32%). For most cancer types, there were significant familial risks and the cumulative risks were higher in monozygotic than dizygotic twins. Heritability of cancer overall was 33% (95% CI, 30%-37%). Significant heritability was observed for the cancer types of skin melanoma (58%; 95% CI, 43%-73%), prostate (57%; 95% CI, 51%-63%), nonmelanoma skin (43%; 95% CI, 26%-59%), ovary (39%; 95% CI, 23%-55%), kidney (38%; 95% CI, 21%-55%), breast (31%; 95% CI, 11%-51%), and corpus uteri (27%; 95% CI, 11%-43%). CONCLUSIONS AND RELEVANCE: In this long-term follow-up study among Nordic twins, there was significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus. This information about hereditary risks of cancers may be helpful in patient education and cancer risk counseling.
Authors: Zsofia Kote-Jarai; Ali Amin Al Olama; Graham G Giles; Gianluca Severi; Johanna Schleutker; Maren Weischer; Daniele Campa; Elio Riboli; Tim Key; Henrik Gronberg; David J Hunter; Peter Kraft; Michael J Thun; Sue Ingles; Stephen Chanock; Demetrius Albanes; Richard B Hayes; David E Neal; Freddie C Hamdy; Jenny L Donovan; Paul Pharoah; Fredrick Schumacher; Brian E Henderson; Janet L Stanford; Elaine A Ostrander; Karina Dalsgaard Sorensen; Thilo Dörk; Gerald Andriole; Joanne L Dickinson; Cezary Cybulski; Jan Lubinski; Amanda Spurdle; Judith A Clements; Suzanne Chambers; Joanne Aitken; R A Frank Gardiner; Stephen N Thibodeau; Dan Schaid; Esther M John; Christiane Maier; Walther Vogel; Kathleen A Cooney; Jong Y Park; Lisa Cannon-Albright; Hermann Brenner; Tomonori Habuchi; Hong-Wei Zhang; Yong-Jie Lu; Radka Kaneva; Ken Muir; Sara Benlloch; Daniel A Leongamornlert; Edward J Saunders; Malgorzata Tymrakiewicz; Nadiya Mahmud; Michelle Guy; Lynne T O'Brien; Rosemary A Wilkinson; Amanda L Hall; Emma J Sawyer; Tokhir Dadaev; Jonathan Morrison; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin S Cooper; Aritaya Lophatonanon; Melissa C Southey; John L Hopper; Dallas R English; Tiina Wahlfors; Teuvo L J Tammela; Peter Klarskov; Børge G Nordestgaard; M Andreas Røder; Anne Tybjærg-Hansen; Stig E Bojesen; Ruth Travis; Federico Canzian; Rudolf Kaaks; Fredrik Wiklund; Markus Aly; Sara Lindstrom; W Ryan Diver; Susan Gapstur; Mariana C Stern; Roman Corral; Jarmo Virtamo; Angela Cox; Christopher A Haiman; Loic Le Marchand; Liesel Fitzgerald; Suzanne Kolb; Erika M Kwon; Danielle M Karyadi; Torben Falck Orntoft; Michael Borre; Andreas Meyer; Jürgen Serth; Meredith Yeager; Sonja I Berndt; James R Marthick; Briony Patterson; Dominika Wokolorczyk; Jyotsna Batra; Felicity Lose; Shannon K McDonnell; Amit D Joshi; Ahva Shahabi; Antje E Rinckleb; Ana Ray; Thomas A Sellers; Hui-Yi Lin; Robert A Stephenson; James Farnham; Heiko Muller; Dietrich Rothenbacher; Norihiko Tsuchiya; Shintaro Narita; Guang-Wen Cao; Chavdar Slavov; Vanio Mitev; Douglas F Easton; Rosalind A Eeles Journal: Nat Genet Date: 2011-07-10 Impact factor: 38.330
Authors: Wen-Qing Li; Ruth M Pfeiffer; Paula L Hyland; Jianxin Shi; Fangyi Gu; Zhaoming Wang; Samsiddhi Bhattacharjee; Jun Luo; Xiaoqin Xiong; Meredith Yeager; Xiang Deng; Nan Hu; Philip R Taylor; Demetrius Albanes; Neil E Caporaso; Susan M Gapstur; Laufey Amundadottir; Stephen J Chanock; Nilanjan Chatterjee; Maria Teresa Landi; Margaret A Tucker; Alisa M Goldstein; Xiaohong R Yang Journal: Carcinogenesis Date: 2014-09-19 Impact factor: 4.944
Authors: Michael E Scheurer; Carol J Etzel; Mei Liu; Jill Barnholtz-Sloan; Fredrik Wiklund; Björn Tavelin; Margaret R Wrensch; Beatrice S Melin; Melissa L Bondy Journal: Am J Epidemiol Date: 2010-09-21 Impact factor: 4.897
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Melissa C Southey; Daniel J Park; Tu Nguyen-Dumont; Ian Campbell; Ella Thompson; Alison H Trainer; Georgia Chenevix-Trench; Jacques Simard; Martine Dumont; Penny Soucy; Mads Thomassen; Lars Jønson; Inge S Pedersen; Thomas Vo Hansen; Heli Nevanlinna; Sofia Khan; Olga Sinilnikova; Sylvie Mazoyer; Fabienne Lesueur; Francesca Damiola; Rita Schmutzler; Alfons Meindl; Eric Hahnen; Michael R Dufault; Tl Chris Chan; Ava Kwong; Rosa Barkardóttir; Paolo Radice; Paolo Peterlongo; Peter Devilee; Florentine Hilbers; Javier Benitez; Anders Kvist; Therese Törngren; Douglas Easton; David Hunter; Sara Lindstrom; Peter Kraft; Wei Zheng; Yu-Tang Gao; Jirong Long; Susan Ramus; Bing-Jian Feng; Jeffrey N Weitzel; Katherine Nathanson; Kenneth Offit; Vijai Joseph; Mark Robson; Kasmintan Schrader; San Wang; Yeong C Kim; Henry Lynch; Carrie Snyder; Sean Tavtigian; Susan Neuhausen; Fergus J Couch; David E Goldgar Journal: Breast Cancer Res Date: 2013-06-21 Impact factor: 6.466
Authors: J Gagnon; E Lévesque; F Borduas; J Chiquette; C Diorio; N Duchesne; M Dumais; L Eloy; W Foulkes; N Gervais; L Lalonde; B L'Espérance; S Meterissian; L Provencher; J Richard; C Savard; I Trop; N Wong; B M Knoppers; J Simard Journal: Curr Oncol Date: 2016-12-21 Impact factor: 3.677
Authors: Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254